ALBANY, New York, November 8, 2016 /PRNewswire/ -- The global market for Cervical Dysplasia features a highly consolidated competitive landscape, with the top three companies accounting for over 76% of the overall market in 2015, observes a recent report by Transparency Market Research. These top vendors, namely Qiagen AG, Hologic Inc., and F. Hoffmann-La Roche Ltd, have strengthened their hold on the market owing to strategies such as collaboration with leading pharmaceutical and biotechnology companies and successful and focused R&D activities. Low product penetration clubbed with vast untapped growth prospects across developing economies is a key incremental opportunity for market players. Thus, companies could benefit from increased focus on strong promotional campaigns in developing economies where nearly 90% of cervical cancer deaths occur on an annual basis. Transparency Market Research estimates that the global cervical dysplasia market will exhibit a healthy CAGR of 7.0% over the period between 2016 and 2024. If the prediction holds true, the market, which valued at US$349.0 mn in 2015, is expected to rise to US$ 640.2 mn by 2024. Download PDF Brochure of Research Insights -http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2241Demand across Developed Regions to Remain Pivotal to Generating Sustainable Profits In terms of diagnosis, the global cervical dysplasia market is dominated by the diagnostic tests segment, which accounted for over 85% of the overall market in 2015. The rising awareness regarding cervical dysplasia and the vast rise in cervical cancer screening programs in developed countries are the key factors attributed to the high share of the segment in the global market. Geographically, the market earns a large share of its overall revenue from developed regions such as North America and Europe, which collectively accounted for over 80% of the overall market in 2015. The trend is expected to remain strong over the forecast period as well. Nevertheless, emerging economies across regions such as Asia Pacific and Latin America also present highly promising growth opportunities. Government-funded Healthcare Screening Programs to Present Vast Growth Opportunities Funds invested by governments towards several healthcare screening programs in a number of developed countries with the aim of preventing several high-incidence cancers are key to the overall development of the global cervical dysplasia market. Over the forecast period as well, the impact of this factor on the overall development of the market is expected to remain significantly high. The rising number of people to undergo cervical screening tests such as Pap smear, HPV, and colposcopy owing to such government initiatives is an excellent growth area for market players.